Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City
27 Maggio 2014 - 3:00PM
Marketwired
Critical Outcome Technologies Selected to Present at Multiple
Investor Conferences in New York City
LONDON, ONTARIO--(Marketwired - May 27, 2014) - Critical Outcome
Technologies Inc. ("COTI" or the "Company") (TSX-VENTURE:COT), the
bioinformatics and accelerated drug discovery company, will be a
featured presenter at two upcoming microcap investor conferences in
New York City. The Company will also be presenting at a dinner
being held by the Financial Investment Analysts of New York on the
evening of May 27th. In addition to providing a Company overview at
all three events, President and CEO Dr. Wayne Danter's presentation
will highlight the Company's lead cancer drug candidate, COTI-2,
the opportunity to do R&D collaborations with CHEMSAS®, and
CHEMFirm, the Company's small molecule profiling and investment due
diligence tool.
On Wednesday, May 28th, Dr. Danter will present at
SeeThruEquity's Microcap Investor Conference being held at Convene
Grand Central in Manhattan. Dr. Danter's presentation is scheduled
to begin at 2:30 p.m. EDT.
On Thursday, May 29th, Dr. Danter will present at the third
annual Marcum Microcap Conference being held at the Grand Hyatt
Hotel in Manhattan. Dr. Danter's presentation is scheduled to begin
at 10:00 a.m. EDT and will be available via a live webcast. To
access the webcast, go to http://wsw.com/webcast/marcum2/cot.v.
"These important presentations provide the Company with multiple
high impact opportunities to continue raising our profile with more
potential life science investors and customers in the United
States," commented Dr. Danter.
Dr. Danter will also be participating in one‐on‐one meetings
with potential investors and customers, and other interested
parties who are registered to attend these conferences.
About Critical Outcome
Technologies Inc.
COTI is a leading-edge bioinformatics company specializing in
accelerating the discovery and development of small molecules -
dramatically reducing the time and cost to bring new drugs to
market. COTI'S proprietary artificial intelligence system,
CHEMSAS®, utilizes a series of predictive computer models to
identify compounds with a high probability of being successfully
developed from disease specific drug discovery through chemical
optimization and preclinical testing. These compounds are targeted
for a variety of diseases, particularly those for which current
treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com.
Follow @CriticalOutcome on Twitter at
http://twitter.com/CriticalOutcome
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Critical Outcome Technologies Inc.Dr. Wayne DanterPresident
& CEO519-858-5157wdanter@criticaloutcome.comHeisler
CommunicationsTrevor HeislerInvestor
Relations416-500-8061trevor@heislercommunications.com
Grafico Azioni Cotinga Pharmaceuticals (TSXV:COT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Cotinga Pharmaceuticals (TSXV:COT)
Storico
Da Dic 2023 a Dic 2024
